Fancy investing in biotech stocks? Temper exuberance with caution


Industry executives are upbeat about the prospects of China's biotech sector, as Beijing has taken a slew of measures to speed up new drug approval and expect pharmaceutical sales to grow by 15pc from 2019 to 2021 Biotech stocks have the potential to excite and disappoint in equal measure, and investors new to the sector should tread carefully, say investment professionals. Similar to early stage minerals and fossil fuel exploration firms without a profit track record, which are also allowed to list in Hong Kong under separate regulations and disclosure requirements to protect retail investors, biotech companies too are inherently risky.



from Biotech News